Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
David Madigan, Jennifer Shin Department of Statistics, Columbia University, New York, NY, USA Introduction: Substantial evidence suggests that drospirenone-containing oral contraceptives may cause a higher risk of venous thrombotic events than earlier-generation oral contraceptives. Methods: To gain...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2018-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | David Madigan, Jennifer Shin Department of Statistics, Columbia University, New York, NY, USA Introduction: Substantial evidence suggests that drospirenone-containing oral contraceptives may cause a higher risk of venous thrombotic events than earlier-generation oral contraceptives. Methods: To gain insight into recent real-world implications, we conducted an analysis using the US Food and Drug Administration’s Adverse Event Reporting System. Results: Venous thrombotic events continue to be reported at a much higher rate with drospirenone-containing oral contraceptives than the general background. The disproportionality has been rising since 2010. The same behavior is not seen with levonorgestrel-containing oral contraceptives. Conclusion: Our results are consistent with decreased physician and patient awareness of risks associated with drospirenone-containing oral contraceptives. Keywords: drug safety, Yaz, venous thrombotic events, FDA adverse event reporting system, disproportionality |
|---|---|
| Item Description: | 1179-1527 |